Rapidly growing mycobacteria (RGM) bloodstream infections (BSI) are an emerging problem often associated with therapeutic challenges. We review the epidemiology, treatment and outcomes over a 5-year period of a heterogeneous group presenting to our institution with RGM BSI.
Materials and Methods
A retrospective cohort study of patients with primary RGM BSI from January 2006-December 2011 was conducted. Patient characteristics (age, race, sex and comorbidities), infection characteristics (catheter associated, hospital acquired, microbiology and antimicrobial susceptibilities), therapy and outcomes were recorded and compared by species.
Among 32 patients, 33 RGM BSI occurred. Patients had an average of 3-4 comorbidities, most commonly malignancy (45.5%). Most isolates (30.3%) were Mycobacterium fortuitum or Mycobacterium mucogenicum (27.2%), followed by Mycobacterium abscessus/chelonae (18.2%) and Mycobacterium immunogenum (12.2%). In all, 85% were catheter associated and 27.3% were hospital acquired. Empiric therapy was started in 19 (57.6%) patients and among these, it was adequate (at least 2 active agents based on susceptibilities) in 12 (63.2%). Among 21 patients with outcome data, cure was assumed for 14 (66.7%). One death was attributable to RGM BSI. Cure rates were higher among those who received adequate empiric therapy compared to those who did not (83.3% versus 42.9%). In general, antibiotic susceptibility was favorable across species for clarithromycin, amikacin and imipenem.
RGM BSI occurred in a population with multiple comorbidities, most commonly malignancy, and most were catheter associated. Higher cures were seen among those who received adequate empiric therapy and based on susceptibility data, a broad empiric regimen of clarithromycin, amikacin and imipenem would be expected to be adequate.
Key Indexing Terms
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of the Medical Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Brooks GF, Carroll KC. Jawetz, Melnick & Adelberg’s Medical Microbiology. Section III. 25th ed. McGraw Hill. chapter 23. 297-299.
- Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.Clin Microbiol Rev. 2002; 15: 716-746
- Disseminated infection with rapidly growing mycobacteria.Clin Infect Dis. 1993; 16: 463-471
- Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review.Rev Infect Dis. 1991; 13: 1120-1125
- Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review.Bone Marrow Transplant. 1997; 19: 467-470
- Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections.Biol Blood Marrow Transplant. 2000; 6: 361-369
- Rapidly growing mycobacteria. Clinical and microbiologic study of 115 cases.Am J Clin Pathol. 2007; 128: 612-621
- Rapidly growing mycobacteria infection in patients with cancer.Clin Infect Dis. 2010; 51: 422-434
- Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infections: 2009 update from the infectious diseases society of america.Clin Infect Dis. 2009; 49: 1-45
- Management of rapidly growing mycobacterial bacteremia in cancer patients.Clin Infect Dis. 2013; 56: 843-846
- Catheter-related bloodstream infections caused by rapidly growing nontuberculous mycobacteria: a case series including rare species.Diagn Microbiol Infect Dis. 2008; 61: 187-191
- CLSI document M24-A2.Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard—Second Edition. Clinical and Laboratory Standards Institute, Wayne, PA2011
- Venous catheter-associated bacteremia caused by rapidly-growing mycobacteria at a medical center in central Taiwan.J Microbiol Immunol Infect. 2009; 42: 343-350
- An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.Am J Respir Crit Care Med. 2007; 175: 367-416
Accepted: October 29, 2015
Received: September 8, 2015
☆The authors have no financial or other conflicts of interest to disclose.
© 2016 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.